VYNE Therapeutics’ (VYNE) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE) in a research note issued to investors on Monday, Benzinga reports. HC Wainwright currently has a $5.75 price target on the stock.

VYNE Therapeutics Price Performance

VYNE Therapeutics stock opened at $2.71 on Monday. The firm has a fifty day simple moving average of $2.50 and a two-hundred day simple moving average of $2.59. VYNE Therapeutics has a twelve month low of $1.67 and a twelve month high of $8.73.

VYNE Therapeutics (NASDAQ:VYNE) last issued its earnings results on Thursday, February 29th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.30. The company had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.15 million. VYNE Therapeutics had a negative return on equity of 77.46% and a negative net margin of 6,710.38%. As a group, research analysts anticipate that VYNE Therapeutics will post -1 EPS for the current year.

Institutional Investors Weigh In On VYNE Therapeutics

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Parkman Healthcare Partners LLC acquired a new position in VYNE Therapeutics Inc. (NASDAQ:VYNE) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 696,470 shares of the company’s stock, valued at approximately $1,623,000. Parkman Healthcare Partners LLC owned 4.99% of VYNE Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 83.78% of the company’s stock.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.